Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

<div><p>Background</p><p>The optimal transcatheter embolization strategy for patients with unresectable hepatocellular carcinoma (HCC) remains elusive. We conducted a systematic review and network meta-analysis (NMA) of different embolization options for unresectable HCC.</p><p>Methods</p><p>Medical databases were searched for randomized controlled trials evaluating bland transarterial embolization (TAE), conventional TACE, drug-eluting bead chemoembolization (DEB-TACE), or transarterial radioembolization (TARE), either alone or combined with adjuvant chemotherapy, or local liver ablation, or external radiotherapy for unresectable HCC up to June 2017. Random effects Bayesian models with a binomial and normal likelihood were fitted (WinBUGS). Primary endpoint was patient survival expressed as hazard ratios (HR) and 95% credible intervals. An exponential model was used to fit patient survival curves. Safety and objective response were calculated as odds ratios (OR) and accompanying 95% credible intervals. Competing treatments were ranked with the SUCRA statistic. Heterogeneity-adjusted effective sample sizes were calculated to evaluate information size for each comparison. Quality of evidence (QoE) was assessed with the GRADE system adapted for NMA reports. All analyses complied with the ISPOR-AMCP-NCP Task Force Report for good practice in NMA.</p><p>Findings</p><p>The network of evidence included 55 RCTs (12 direct comparisons) with 5,763 patients with preserved liver function and unresectable HCC (intermediate to advanced stage). All embolization strategies achieved a significant survival gain over control treatment (HR range, 0.42–0.76; very low-to-moderate QoE). However, TACE, DEB-TACE, TARE and adjuvant systemic agents did not confer any survival benefit over bland TAE alone (moderate QoE, except low in case of TARE). There was moderate QoE that TACE combined with external radiation or liver ablation achieved the best patient survival (SUCRA 86% and 96%, respectively). Estimated median survival was 13.9 months in control, 18.1 months in TACE, 20.6 months with DEB-TACE, 20.8 months with bland TAE, 30.1 months in TACE plus external radiotherapy, and 33.3 months in TACE plus liver ablation. TARE was the safest treatment (SUCRA 77%), however, all examined therapies were associated with a significantly higher risk of toxicity over control (OR range, 6.35 to 68.5). TACE, DEB-TACE, TARE and adjuvant systemic agents did not improve objective response over bland embolization alone (OR range, 0.85 to 1.65). There was clinical diversity among included randomized controlled trials, but statistical heterogeneity was low.</p><p>Conclusions</p><p>Chemo- and radio-embolization for unresectable hepatocellular carcinoma may improve tumour objective response and patient survival, but are not more effective than bland particle embolization. Chemoembolization combined with external radiotherapy or local liver ablation may significantly improve tumour response and patient survival rates over embolization monotherapies. Quality of evidence remains mostly low to moderate because of clinical diversity.</p><p>Systematic review registration</p><p>CRD42016035796 (<a href="http://www.crd.york.ac.uk/PROSPERO" target="_blank">http://www.crd.york.ac.uk/PROSPERO</a>).</p></div

Objective response network meta-analysis (Random effects plot).

<p>Different treatments are reported in order of efficacy ranking according to the SUCRA statistic. Black circles denote the posterior median and the black lines denote the associated 95% CrI. Numbers represent odds ratios (OR) and 95% CrIs. The combination of TACE and ablation was found to be the most effective treatment (SUCRA 99%).</p

Strength and quality of evidence.

<p>QoE was graded as recommended for network meta-analyses on the basis of clinical diversity (between-trial heterogeneity of patient characteristics and/or study design), indirectness (absence of direct randomized comparisons), and imprecision (we chose a threshold of information fraction <50%). Effective sample size n for each comparison is shown along with information fraction (IF; %) in parentheses (compared to n = 560 for a hypothetical well-powered randomized study to detect a survival benefit of HR = 0.70 at 2 years). Color-coded representation of QoE; very low (light gray), low (yellow), moderate (green). There were no cases of high QoE observed.</p

Serious adverse events network meta-analysis (Random effects forest plot).

<p>Different treatments are reported in order of safety ranking according to the SUCRA statistic. Black circles denote the posterior median and the black lines denote the associated 95% CrI. Numbers represent odds ratios (OR) and 95% CrIs. TARE was found to be the safest treatment (SUCRA 90%).</p

Survival model.

<p>Projected survival curves for each treatment were fitted with an exponential model up to 5 years. Conventional TACE was the most common comparator in the overall network of evidence and was used as the anchor treatment because it had the largest sample size. Absolute survival estimates of TACE at different time points were calculated with a standard random effects proportional model weighted by patient sample for each trial (black circles). Median patient survival (half-life) for each treatment was then calculated by combining the fitted hazard rate (exponential decay constant) of the anchor treatment with the pairwise posterior median HR calculated by the Bayesian model for the respective treatment.</p

Network of evidence.

<p>Straight black lines denote direct head-to-head randomized comparisons. Numbers refer to the number of RCTs with direct comparisons available for each link and the size of circles is proportional to the pooled sample size (patients) available for each treatment node.</p

Included randomized controlled trials and baseline patient demographics and index tumour characteristics.

<p>Included randomized controlled trials and baseline patient demographics and index tumour characteristics.</p

Patient survival.

<p>Forest plots (random effects) of direct frequentist analyses (RevMan, Cochrane). Risk of bias assessment by the Cochrane Collaboration tool is presented as well.</p

Serious adverse events.

<p>Forest plots (random effects) of direct frequentist analyses of patient survival (RevMan, Cochrane). Risk of bias assessment by the Cochrane Collaboration tool is presented as well.</p

Objective response.

<p>Forest plots (random effects) of direct frequentist analyses of patient survival (RevMan, by Cochrane). Risk of bias assessment by the Cochrane Collaboration tool is presented as well.</p